Search
aTyr Pharma Ord Shs
LIFEAdd to Watchlist
36.830USD
+0.430+1.18%
Market hours 09/18, 13:01（ET）
2.35BMarket Cap
LossP/E TTM
aTyr Pharma Ord Shs (LIFE) Stock Price Target & Forecast
Analyst Rating
Based on 9 analysts giving stock ratings to aTyr Pharma Ord Shs in the past month.
Buy
4 Strong Buy
5 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
34.571USD-14.17%
LIFE Analyst Recommendation Trends
In the current month, LIFE has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. LIFE average Analyst price target in the last month is 34.571.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
4
4
4
4
4
0
0
0
5
5
5
5
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9
9
9
9
9
0
0
0
LIFE Analyst Rating for Peer Comparison
Updated: Sep 17, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Ascendis Pharma A/S
ASND
10
10
0
0
0
20
Financial Forecasting
Based on analysts' estimates, LIFE EPS is projected to reach 0.303 in FY2026Q3, following reported EPS of 0.308 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
0.39
-0.98
0.24
0.30
0.37
Actual
0.39
-3.57
0.31
--
--
Surprise
+1.19%
-265.33%
+27.77%
--
--
FAQs
What is aTyr Pharma Ord Shs's expected revenue for the next quarter?
aTyr Pharma Ord Shs's expected revenue is 163.37M.
What is aTyr Pharma Ord Shs's price target?
Analysts forecast that aTyr Pharma Ord Shs's price target is USD 34.57, with the highest forecast at USD 40.00 and the lowest forecast at USD 32.00.
How have aTyr Pharma Ord ShsLIFE's recent earnings per share performed?
The market expectation was USD 0.31, while aTyr Pharma Ord ShsLIFE's earnings per share (EPS) for the previous quarter was USD -3.57. EPS for the next quarter is expected at USD 0.30.
What is the analyst rating for aTyr Pharma Ord Shs?
Based on the ratings of aTyr Pharma Ord Shs's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.